Cathie Wood made several notable trades across her ARK ETFs on Tuesday, December 16, 2025, according to daily trade filings. The filings show ARK adding to crypto-related names such as Bullish (BLSH) and Brera Holdings (SLMT), as well as genomics-focused diagnostics firm Caris Life Sciences (CAI), while continuing to trim its stake in consumer tech company Ibotta (IBTA).
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
What Stocks Did Cathie Wood Buy Today?
On the buying side, ARK’s largest move of the day was in Bullish. The firm purchased 42,122 shares across the ARK Innovation ETF (ARKK), ARK Next Generation Internet ETF (ARKW), and ARK Fintech Innovation ETF (ARKF), for a total value of about $1.8 million. This followed a much larger purchase the day before, signaling growing confidence in the crypto-focused trading platform.
ARK also added 59,196 shares of Brera Holdings, a small-cap company that recently rebranded as a crypto infrastructure firm, across ARKK, ARKW, and ARKF, valued at around $129,000.
In addition, ARK increased its exposure to healthcare innovation. Through the ARK Genomic Revolution ETF (ARKG), the firm bought 33,247 shares of Caris Life Sciences, investing roughly $887,694. The move reflects ARK’s continued focus on genomics and data-driven medicine.
Let’s see how these stocks perform using the TipRanks Stock Comparison Tool:
Why Is Cathie Wood Selling Ibotta Stock?
On the selling side, the ace hedge fund manager appeared to leverage the 3.9% surge in Ibotta stock. She sold 38,911 shares across her ARKW and ARKF ETFs for a total value of about $818,000. Wood has been steadily reducing her Ibotta stake to reallocate capital toward more disruptive technology and space-related investments.
According to TipRanks, IBTA stock has received a Hold consensus rating, with one Buy, three Holds, and two Sells assigned in the last three months. The average stock price target for Ibotta is $28.00, suggesting a potential upside of 28.21% from the current level.
